�y��vlog

Food and Drug Administration as the first coagulation factor replacement therapy for people with a rare blood disorder known as hereditary Factor X deficiency.

As Avorn notes in his editorial, there is "reason to wonder how the use of an obscure recombinant coagulation factor marketed exclusively to hematologists became used so widely."

These observations suggest that coagulation factor mutations should be explored more fully in human cancers.